PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study

RATIONALE: PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses. PATIENT CONCERNS: However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined. DIAGNOSES AND INTERVENTATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosso, Davide, Pagliuca, Martina, Sonpavde, Guru, Pond, Gregory, Lucarelli, Giuseppe, Rossetti, Sabrina, Facchini, Gaetano, Scagliarini, Sarah, Cartenì, Giacomo, Daniele, Bruno, Morelli, Franco, Ferro, Matteo, Puglia, Livio, Izzo, Michela, Montanaro, Vittorino, Bellelli, Teresa, Vitrone, Francesca, De Placido, Sabino, Buonerba, Carlo, Di Lorenzo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478302/
https://www.ncbi.nlm.nih.gov/pubmed/28614217
http://dx.doi.org/10.1097/MD.0000000000006817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478302/
https://www.ncbi.nlm.nih.gov/pubmed/28614217
http://dx.doi.org/10.1097/MD.0000000000006817

Ejemplares similares